2022 TECHNICAL BULLETINS:
Biocompatibility and Devices
Biocompatibility is the ability of an implant material to function in vivo without eliciting detrimental local or systemic responses in the body. Prior to their use in human fracture fixation, biomaterials undergo tissue and animal testing to determine their safety and efficacy. We offer a range of safety evaluation and biocompatibility services for medical devices.
2021 TECHNICAL BULLETINS:
Dermal Burn Modeling
Due to Comparative Biosciences, Inc. unique and extensive experience in dermatology studies and state-of-theart facilities, we have the skill and expertise to accelerate new dermatology drugs, biologics, and devices from discovery through the drug development process, to regulatory submission and studies in man.
2021 TECHNICAL BULLETINS:
Surgical Models and Services
Comparative Biosciences, Inc. currently offer a variety of surgical models and services on multiple rodent species (rat, mouse, guinea pig, hamster, and gerbil) at several of our AAALAC-accredited production facilities in North America.
2021 TECHNICAL BULLETINS:
Subcutaneous Implant Procedure + Video
In medicine, a subcutaneous implant, or subcutaneous pellet, is an implant that is delivered under the skin into the subcutaneous tissue by surgery or injection and is used to deliver a drug for a long period of time. Watch our video procedure!
2021 TECHNICAL BULLETINS:
Intraocular Lens Implantation
Comparative Biosciences, Inc. provides a range of sophisticated and customized intraocular implant models. We are offering intraocular lens implantation surgery for cataract treatment particularly in both pigmented and albino rabbits.
2019 TECHNICAL BULLETINS:
Oxygen Induced Retinopathy
Our highly specialized staff is experienced in providing exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathology/immunohistochemistry related to the eye.
2019 TECHNICAL BULLETINS:
Dermatology Studies
Due to CBI’s unique and extensive experience in dermatology studies and state-of-theart facilities, we have the skill and expertise to accelerate new dermatology drugs, biologics, and devices from discovery through the drug development process, to regulatory submission and studies in man.
2019 TECHNICAL BULLETINS:
CBI Overview
A Contract Research Organization by Scientists, for Scientists.
Comparative Biosciences, Inc., a premier preclinical contract research organization (CRO), is committed to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with a solid track record in preclinical research and drug development capabilities.
January 2019
Intraocular Lens Implantation Studies
Intraocular Lens Implantation Preclinical Models at CBI. CBI provides a range of sophisticated and customized intraocular implant models.
December 2018
Pompe Disease Studies
Pompe disease is caused by pathogenic variations in the acid alpha-glucosidase (GAA) gene. Close to 500 different GAA gene variations have been identified in families with this disorder.
Glycogen Storage Disease Histopathology on Human Muscle Biopsies from patients affected with a Glycogen Storage Disease.
November 2018
Fibrosis Inflammation Studies
Tissue damage and inflammation are important triggers for regeneration and fibrosis.
CBI focuses on the pathways leading from tissue damage to inflammation, from inflammation to fibrosis and from fibrosis to function.
June 2018
Central Nervous System Studies
CBI offers a variety of customized, investigative, and specialized surgical CNS pharmacology and efficacy models.
If you have a specialized CNS study requirement, our skilled scientists can facilitate the protocol development as well as the conduct of these novel, difficult and specialized projects.
Visit CBI at SOT 2018 – Annual Meeting and Tox Expo
SOT 2018 March 11 – 15 San Antonio, Texas
February 2018
Bronchopulmonary Dysplasia
CBI Congratulates Meridigen Biotech Co., Ltd on their successful IND for their project!
January 2018
Scleroderma in Tight Skin Mouse Model
CBI offers preclinical research studies in dermal and pulmonary fibrosis. In addition to our validated bleomycin-induced fibrosis models, we also now offer fibrosis studies utilizing the JAX Tight Skin Mouse Model.
December 2017
Toxicology Capabilities: From Discovery to IND
CBI offers a complete program of preclinical research services to support a range of your toxicology requirements. We have experience with early
assessment of new molecules including single dose, multiple dose and targeted studies, as well as directed or investigative toxicology, and IND enabling toxicology programs.
August 2017
Dermal Pharmacology and Toxicology at CBI
Check out our latest updates on our pharmacology models and toxicology capabilities in dermatology.
July 2017
Otic and Auditory Studies at CBI
Comparative Biosciences continues to evolve with niche and specialty preclinical, IND enabling GLP or non-GLP otic and auditory toxicology, efficacy, pharmacokinetics/pharmacodynamics in relevant animal species.
June 2017
See you at ARVO 2017!
CBI will be attending the ARVO annual meeting in Baltimore, MD this year. Please contact our business development team to set up a meeting about your upcoming research needs!
May 2017
Dermatology Capabilities
As the largest organ in the human body, skin plays a vital role in overall health and well-being. With over 20 years of experience, Comparative Biosciences has an arsenal of innovative and validated pharmacological models for dermatological therapeutics.
April 2017
Hyperoxygenation Models at CBI
Clinical indications caused by neonatal hyperoxygenation such as bronchopulmonary fibrosis and retinopathy of prematurity have created an unmet medical need for therapeutic treatments. Comparative Biosciences has multiple robust and validated methods, ready to advance your therapeutic development.
March 2017